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Background—Remodeling of the extracellular matrix plays an important role during the pathogenesis of atherosclerosis
and restenosis. The matrix glycoprotein thrombospondin-1 (TSP1) inhibits endothelial cell proliferation and migration
in vitro. In contrast, TSP1 facilitates the growth and migration of cultured vascular smooth muscle cells. Accordingly,
we investigated the hypothesis that administration of anti-TSP1 antibody could facilitate reendothelialization and inhibit
neointimal thickening in balloon-injured rat carotid artery.
Methods and Results—Sprague-Dawley rats were subjected to left common carotid artery denudation, after which arteries
were treated with C6.7 anti-TSP1 or control antibody. Evans blue dye staining 2 weeks after injury disclosed
significantly increased reendothelialization in arteries treated with C6.7 antibody compared with the control group, and
this effect was associated with increased number of proliferating cell nuclear antigen–positive endothelial cells. In
contrast, treatment with C6.7 antibody decreased the number of proliferating cell nuclear antigen–positive vascular
smooth muscle cells in the injured arterial wall. Neointimal thickening was correspondingly attenuated to a statistically
significant degree in arteries receiving C6.7 antibody versus the control group at both the 2-week and 4-week time
points.
Conclusions—Intra-arterial delivery of antibody against TSP1 facilitated reendothelialization and reduced neointimal
lesion formation after balloon denudation. (Circulation. 1999;100:849-854.)
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Endothelial dysfunction triggers a cascade of events thatcontribute to the pathogenesis of atherosclerosis and
restenosis, including platelet activation and aggregation, vas-
cular smooth muscle cell (VSMC) proliferation and migra-
tion, and deposition of extracellular matrix (ECM) compo-
nents into the vessel wall.1–6 It has become increasingly clear
that multiple cytokines, in conjunction with the ECM and
integrins, orchestrate vascular remodeling in response to
arterial injury.7–9
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The vascular ECM is a complex of different macromole-
cules organized into a highly ordered architectural framework
that provides the structural supporting element for the vascu-
lar cells and surrounding tissues. ECM components also
participate in the regulation of other highly specialized
cellular functions triggered by growth factors and cytokines,
including cell adhesion, migration, proliferation, and differ-
entiation.7,10–12 The matrix protein thrombospondin-1 (TSP1)
is synthesized and secreted by activated platelets13 and a
variety of cell types including endothelial cells (ECs),14,15
macrophages,16 fibroblasts,17 and VSMCs.18 TSP1 is a 450-
kDa homotrimeric glycoprotein that interacts with multiple
extracellular macromolecules and cell surface receptors, thus
exerting a wide range of functions.19,20 Cell culture experi-
ments have demonstrated the ability of TSP1 to induce arrest
of EC growth.21,22 The spontaneous development of angio-
genic tube-like structures is also inhibited by TSP1 both in
vitro and in vivo.23–25 In marked contrast, TSP1 promotes
VSMC proliferation and migration26,27 and plays a stimula-
tory role in platelet activation and aggregation.28,29 These
findings suggest that TSP1 may play an important role in the
pathogenesis of atherosclerosis and restenosis. Consistent
with this notion, TSP1 expression has been associated with
atherosclerotic lesions, acute vascular injury, hypercholester-
olemia, and hypertension.15,30–35 In the present study, mono-
clonal neutralizing anti-TSP1 antibody was locally delivered
to the arterial wall after balloon angioplasty in the rat carotid
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artery to evaluate in vivo the role of TSP1 on vascular repair
after acute injury. We show that local administration of
anti-TSP1 antibody expedited reendothelialization and re-
duced neointimal thickening.
Methods
Balloon Angioplasty, Antibody Delivery, and
Evaluation of Reendothelialization and
Neointimal Thickening
Balloon angioplasty in the left common carotid artery of male
Sprague-Dawley rats was performed essentially as described by
Clowes et al.2 Immediately after angioplasty, protein A–purified
mouse monoclonal anti-TSP1 antibody C6.729 or control nonspecific
IgG antibody MOPC-21 (Sigma Chemical) was delivered intra-ar-
terially by use of the dwell technique (100 mg of IgG in 100 mL of
sterile 0.1% BSA/PBS; 30 minutes), This was followed by 1 week of
continuous periarterial delivery by osmotic pump (Alzet, model 2
ML1, Alza) as described previously.36,37 In brief, the common
carotid artery was further isolated and dissected free of fat and
connective tissue and a superficial longitudinal incision into the
adventitia was made with a modified coronary artery surgical blade
to ensure penetration of the antibody to the external muscular layer
of the media. A sterile microcatheter was placed adjacent to the
injured portion of the artery and secured by suturing it directly to the
adjacent musculature. The proximal end of the microcatheter was
heat-sealed, and longitudinal perforations were made on the catheter
at the site adjacent to the injured arterial segment. The distal end of
the microcatheter was passed through the lateral neck and connected
to the osmotic pump. The pump was filled with C6.7 or MOPC-21
control antibody (400 mg IgG in a final volume of 2 mL of sterile
PBS). The wounds were cleaned with saline and wiped dry with a
sterile cotton swab. Fascia surrounding the artery was sutured closed.
The pump was placed and sutured in a pocket made in the back of the
rat. One week after infusion at 10 mL/h, the pump and the
microcatheter were removed from the rats under anesthesia.
The study comprised 13 arteries treated with C6.7 antibody (n57,
2 weeks; n56, 4 weeks) and 18 arteries treated with control antibody
(n59, 2 weeks; n59, 4 weeks). Two carotid arteries from the control
group (1 at each time point) developed thrombosis after balloon
injury and were therefore discarded. All vessels treated with C6.7
antibody were patent at the time the animals were killed. Animals
received an intravenous injection of 1 mL 0.5% Evans blue 30
minutes before they were killed to identify nonendothelialized
surfaces. The extent of reendothelialization and neointimal thicken-
ing 2 and 4 weeks after angioplasty was evaluated by planimetric
analysis as previously described.38
To assess antibody delivery into the arterial wall, animals were
killed 3 days after angioplasty. Methanol-fixed arteries were sec-
tioned longitudinally for immunohistochemistry with the use of
rat-adsorbed, biotinylated horse anti-mouse antibody (Vector Labo-
ratories) and a biotin/streptavidin-horseradish peroxidase detection
system (Signet Laboratories). A polyclonal horse anti-goat antibody
was used for negative control.
Antibody Bioassay
VSMC migration was assessed with a modified Boyden chamber
(Neuroprobe) and platelet-derived growth factor (PDGF) BB (10
ng/mL) as the chemoattractant.39 Rat aortic VSMCs were isolated as
previously described,40 seeded in the upper compartment (2.53105
cells in 50 mL of 1% FBS/DMEM), and incubated for 30 minutes in
the absence or in the presence of C6.7 antibody. After 5 hours of
incubation, migration was quantified by counting the number of cells
on the lower side of the filter from 3 randomly chosen high-power
(3400) fields.
Expression Studies and Assessment of Proliferative
Activity After Balloon Injury
Arteries were harvested and adventitia and connective tissues were
removed as cleanly as possible. Preparation of arterial extracts and
Western blot analysis were carried out as previously described.41
Blots were probed with rabbit polyclonal anti-TSP1 antibody (a gift
from Dr Jack Lawler) and mouse monoclonal anti-tubulin antibody
(Calbiochem). After incubation with horseradish-peroxidase–conju-
gated secondary antibodies, immunocomplexes were visualized with
ECL reagent (Amersham). Proliferative activity in injured arteries
was evaluated by immunohistochemical analysis of proliferating cell
nuclear antigen (PCNA) expression as previously described.38 ECs
were identified by immunohistochemistry with the use of a mouse
monoclonal anti-CD31 antibody (1:40 dilution in 1% BSA/PBS)
(PharMingen).
Statistical Analysis
Results are expressed as mean6SEM. Differences in the number of
migrating cells and PCNA-immunoreactive cells were evaluated by
use of a 2-tailed, unpaired Student’s t test. Differences in the extent
of reendothelialization and neointimal thickening were evaluated by
use of ANOVA and Scheffe´’s F post hoc test. Differences were
considered significant at P,0.05.
Results
Induction of TSP1 Expression After Balloon
Angioplasty and Biological Activity of
C6.7 Antibody
TSP1 protein expression in the rat carotid artery was greatly
upregulated as early as 1 day after angioplasty, and its
expression was maintained up to 2 weeks (Figure 1A). These
findings are consistent with previous Northern blot and
immunohistochemical analysis demonstrating a rapid induc-
tion of TSP1 in balloon-injured arteries.33,34,42
We next evaluated the biological activity of neutralizing
anti-TSP1 antibody C6.7. Treatment with C6.7 antibody
inhibited in a dose-dependent manner PDGF BB–dependent
migration of cultured VSMCs (Figure 1B). When C6.7
antibody solution containing 50 mg/mL IgG was incubated
for 6 days at 37°C, its inhibitory effect on PDGF BB–
mediated VSMC migration was comparable to that elicited by
the same concentration of fresh antibody. Thus prolonged
incubation of C6.7 antibody at body temperature did not
appear to reduce its biological activity.
C6.7 Antibody Delivery Facilitates
Reendothelialization After Balloon Angioplasty
To assess the role of TSP1 on the vascular response to injury,
neutralizing C6.7 antibody was delivered intra-arterially by
use of the dwell technique followed by continuous delivery
with an osmotic pump. We first evaluated the presence of
mouse monoclonal C6.7 antibody in the injured arterial wall
3 days after angioplasty. Longitudinal sections were incu-
bated with horse anti-mouse IgG, which elicited immunore-
activity within the media and adventitia (Figure 1C, left). No
signal was detected when horse anti-goat IgG was used as the
secondary antibody (Figure 1C, right). These studies demon-
strated the presence of mouse monoclonal C6.7 antibody in
the injured arterial wall.
To evaluate the effect of C6.7 antibody on reendotheli-
alization and neointimal thickening, rats were implanted with
the osmotic pump delivery system for 1 week after balloon
angioplasty. Animals received an intravenous injection of 1
mL 0.5% Evans blue dye before they were killed to evaluate
the extent of reendothelialization (Figure 2A). Two weeks
after angioplasty, C6.7-treated arteries disclosed a 60% in-
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crease in reendothelialized area as compared with the control
group (46.1762.04% in the control group vs 73.3163.26 in
the C6.7 group, P50.0016). No statistically significant dif-
ferences between the control group and the C6.7 group were
seen at 4 weeks after angioplasty.
Effect of C6.7 Antibody Delivery on Cellular
Proliferation and Neointimal Thickening
We have previously shown that PCNA expression after
balloon angioplasty correlates temporally and spatially with
cellular proliferation in the rat carotid artery.43 Thus PCNA
immunostaining was used to assess the effect of C6.7 anti-
body on cellular proliferation in balloon-injured arteries. Two
weeks after angioplasty, C6.7-treated arteries disclosed a
higher number of PCNA-positive cells at the luminal surface
(1.5760.26 mm21 in the control group vs 3.0960.49 mm21 in
the C6.7 group, P,0.05) (Figure 2, C and D). Adjacent
sections were analyzed with anti-CD31 antibody to identify
ECs. In agreement with the results of Evans blue staining,
CD31 immunoreactivity at the luminal edge of the neointima
was more abundant in arteries treated with C6.7 antibody than
in control arteries (Figure 2D, and data not shown). Thus
accelerated reendothelialization after balloon angioplasty on
administration of C6.7 antibody appeared to correlate with
increased EC proliferation.
Consistent with the kinetics of proliferation in balloon-
injured rat carotid arteries,43,44 PCNA immunolocalization at
2 weeks after angioplasty was limited predominantly to the
neointima (Figure 2D). Treatment with C6.7 antibody re-
duced the number of neointimal PCNA-positive VSMCs by
approximately half (23.664.08 mm21 in the control group vs
11.9262.46 mm21 in the C6.7 group, P,0.05) (Figure 2C).
As expected, the number of PCNA-positive cells at 4 weeks
was reduced in the neointima of both control and C6.7-treated
arteries (data not shown).
Collectively, the above results suggest that administration
of anti-TSP1 antibody inhibited VSMC hyperplasia in vivo.
The intima-to-media (I/M) ratio was correspondingly reduced
by '63% in the C6.7 group at both the 2- and 4-week time
points (1.3360.04 in the control group vs 0.8360.05 in the
C6.7 group at 2 weeks, P,0.0001; 1.5760.07 in the control
group vs 0.9460.04 in the C6.7 group at 4 weeks, P,0.0001)
(Figure 2B). Of note, although control arteries showed a
statistically significant higher I/M ratio at 4 weeks as com-
pared with the 2-week time point (P50.03), neointimal
thickening in the C6.7-treated arteries remained nearly un-
changed during the same time interval.
Discussion
The expression pattern of TSP1 is consistent for a role of this
matrix protein on the pathogenesis of atherosclerosis and
restenosis15,30–35 (this study). Previous in vitro studies also
support this notion. For example, TSP1 inhibits migration and
proliferation of cultured ECs,21,22 and several studies have
suggested that this might translate into inhibition of angio-
genesis in vivo.23,24,45–47 The extent to which these observa-
tions may be extrapolated to reendothelialization after bal-
loon injury, however, has never been tested. Given the ability
of TSP1 to promote VSMC proliferation and migration in
vitro,26,27 TSP1 would potentially represent a unique matrix
protein with dual effects on ECs and VSMCs that might both
delay EC regeneration and facilitate neointimal lesion forma-
tion after balloon injury. The present study demonstrates that
administration of the anti-TSP1 antibody C6.7 after balloon
angioplasty in the rat carotid artery expedited reendotheli-
alization and reduced neointimal thickening, and these effects
were associated with increased EC proliferation and reduced
VSMC growth.
Recent studies have demonstrated direct effects of TSP1
on ECs that are consistent with our observations. For
example, addition of TSP1 to ECs that had already formed
Figure 1. TSP1 expression and C6.7 antibody delivery after bal-
loon injury. A, Tissue extracts were prepared from uninjured
(UN) arteries and at the indicated times after angioplasty. TSP1
and tubulin expression was evaluated by Western blot analysis.
B, Rat VSMC migration was evaluated with the use of a Boiden
chamber and PDGF BB as chemoattractant. Cells were treated
with the indicated concentrations of fresh C6.7 antibody or with
C6.7 antibody that had been previously incubated at 37°C for 6
days (open bar). After 5 hours of incubation, cells were counted
in 3 randomly chosen high power fields (HPF) from the lower
side of each filter. All assays were performed in triplicate. C,
Arterial sections were incubated with horse anti-mouse second-
ary antibody to assess the presence of mouse monoclonal C6.7
antibody (black arrows). No signal was detected when using
horse anti-goat secondary antibody. White arrows point to the
external elastic lamina.
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stable focal adhesions on a fibronectin substrate stimulated
focal adhesion disassembly.48 Moreover, TSP1 inhibited
angiogenesis both in vitro and in vivo,23–25 and some
observations suggested that TSP1 might act as a physio-
logical inhibitor of angiogenesis.24,45– 47 The ability of C6.7
antibody to inhibit neointimal thickening after balloon
angioplasty is also in agreement with previous in vitro
studies demonstrating a direct role of TSP1 in promoting
VSMC growth and migration.26,27,49 –51
In addition to the direct effect of TSP1 on VSMC prolif-
eration, it is noteworthy to point out that several studies in the
rat carotid model of vascular injury have clearly established
an inverse relation between endothelial integrity and VSMC
proliferation.52–55 Moreover, application of various EC mito-
gens that accelerated reendothelialization attenuated neointi-
mal lesion formation.38,56,57 Thus expeditious reendotheli-
alization in C6.7-treated arteries probably contributed to
reduced neointimal thickening.
In conclusion, this study demonstrates a favorable effect
of anti-TSP1 antibody on both reendothelialization and
neointimal hyperplasia after balloon angioplasty. Thus the
results imply the potential utility of a novel treatment
strategy in which inhibition of a matrix protein simulta-
neously promotes EC growth and reendothelialization and
inhibits VSMC proliferation. This could be a powerful
therapeutic strategy to inhibit neointimal thickening after
balloon denudation.
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